ArticleWorld journal of surgical oncology2026
Mediastinal lymphadenectomy strategy for Siewert II adenocarcinoma of the esophagogastric junction: a retrospective cohort study.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSiewert type II adenocarcinoma of the esophagogastric junction (AEG) is characterized by complex, bidirectional lymph node metastasis. This retrospective study evaluates recurrence and mortality risks associated with varying extents of mediastinal lymph node dissection.
methodsA retrospective analysis was conducted on 221 Siewert type II AEG patients who underwent radical surgery (McKeown or Left Thoracotomy [LT] approach) between June 2016 and October 2023. Patients were grouped according to the extent of lymphadenectomy: complete mediastinal and abdominal lymph node dissection (CMAD) or middle/lower mediastinal and abdominal lymph node dissection (MLMAD). To ensure comparability, patients in the CMAD group were matched 1:1 with those in the MLMAD group using propensity score matching (PSM). Prognostic outcomes were analyzed using Kaplan-Meier curves, and Cox regression analysis was performed to identify risk factors.
resultsCMAD was associated with significantly improved overall survival (OS) (HR = 0.37, 95%CI:0.23-0.60; P < 0.001) and disease-free survival (DFS) (HR = 0.36, 95%CI:0.22-0.58; P < 0.001) compared to MLMAD before PSM; these benefits persisted after PSM (OS HR = 0.44, P = 0.01; DFS HR = 0.44, P = 0.02). Upper mediastinal metastasis was observed in 4.3% of patients. Dissection of upper mediastinal stations, particularly 2R, 4R, and 8U, contributed to the survival benefit. Removal of more than 11 lymph nodes was associated with improved survival. The McKeown approach enabled a more comprehensive upper mediastinal and abdominal lymphadenectomy compared to LT (P < 0.001), without increasing complication rates or hospital stay.
conclusionThe findings suggest that a surgical strategy involving the comprehensive removal of mediastinal and abdominal lymph nodes, when applied to selected patients in a high-volume center, is associated with superior survival outcomes compared to more limited dissections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.